T. Rowe Price Associates’s BridgeBio Pharma BBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $41.5M | Sell |
961,216
-203,751
| -17% | -$8.8M | ﹤0.01% | 774 |
|
|
2025
Q1 | $40.3M | Buy |
1,164,967
+173,729
| +18% | +$6.01M | 0.01% | 785 |
|
|
2024
Q4 | $27.2M | Buy |
991,238
+180,773
| +22% | +$4.96M | ﹤0.01% | 914 |
|
|
2024
Q3 | $20.6M | Sell |
810,465
-14,353
| -2% | -$365K | ﹤0.01% | 985 |
|
|
2024
Q2 | $20.9M | Buy |
824,818
+20,862
| +3% | +$528K | ﹤0.01% | 957 |
|
|
2024
Q1 | $24.9M | Buy |
803,956
+145,594
| +22% | +$4.5M | ﹤0.01% | 922 |
|
|
2023
Q4 | $26.6M | Buy |
658,362
+596,386
| +962% | +$24.1M | ﹤0.01% | 878 |
|
|
2023
Q3 | $1.64M | Buy |
61,976
+2,220
| +4% | +$58.6K | ﹤0.01% | 1550 |
|
|
2023
Q2 | $1.03M | Buy |
59,756
+4,555
| +8% | +$78.4K | ﹤0.01% | 1792 |
|
|
2023
Q1 | $916K | Sell |
55,201
-11,321
| -17% | -$188K | ﹤0.01% | 1830 |
|
|
2022
Q4 | $507K | Sell |
66,522
-16,764
| -20% | -$128K | ﹤0.01% | 2126 |
|
|
2022
Q3 | $828K | Sell |
83,286
-6,911
| -8% | -$68.7K | ﹤0.01% | 1857 |
|
|
2022
Q2 | $819K | Buy |
90,197
+23,973
| +36% | +$218K | ﹤0.01% | 1979 |
|
|
2022
Q1 | $672K | Buy |
66,224
+24,238
| +58% | +$246K | ﹤0.01% | 2202 |
|
|
2021
Q4 | $700K | Sell |
41,986
-2,507
| -6% | -$41.8K | ﹤0.01% | 2219 |
|
|
2021
Q3 | $2.09M | Sell |
44,493
-498,672
| -92% | -$23.4M | ﹤0.01% | 1705 |
|
|
2021
Q2 | $33.1M | Sell |
543,165
-62,825
| -10% | -$3.83M | ﹤0.01% | 1173 |
|
|
2021
Q1 | $37.3M | Buy |
605,990
+575,776
| +1,906% | +$35.5M | ﹤0.01% | 1099 |
|
|
2020
Q4 | $2.15M | Buy |
30,214
+3,141
| +12% | +$223K | ﹤0.01% | 1613 |
|
|
2020
Q3 | $1.02M | Buy |
27,073
+9,118
| +51% | +$342K | ﹤0.01% | 1786 |
|
|
2020
Q2 | $586K | Buy |
17,955
+244
| +1% | +$7.96K | ﹤0.01% | 1990 |
|
|
2020
Q1 | $514K | Buy |
+17,711
| New | +$514K | ﹤0.01% | 1982 |
|